Ohio State Navbar

Hampel Re-elected President of Genetic Board

COLUMBUS, Ohio – Heather Hampel (43035), a cancer genetic counselor at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, has been re-elected for a second term as president of the American Board of Genetic Counseling.

Hampel provides genetic counseling for patients at high risk for hereditary cancer syndromes, including breast-ovarian cancer syndrome, Lynch syndrome (a predisposition to colorectal and endometrial cancers) and familial adenomatous polyposis. Hampel, who is clinical associate director of the Division of Human Genetics at The Ohio State University Medical Center, also coordinates research studies to identify novel cancer susceptibility genes.

The American Board of Genetic Counseling is the credentialing organization for the genetic counseling profession in North America, providing certification and recertification of qualified professionals. In addition, it is responsible for the accreditation of graduate programs in genetic counseling.

Hampel is also a member the National Society of Genetic Counselors, the American Society of Human Genetics and the Ohio Cancer Genetics Network. She represents the OSUCCC-James on the National Comprehensive Cancer Network’s Genetic/Familial High-Risk Assessment Panel.

For more information about the Clinical Cancer Genetics and Medical Genetics Programs at The James, call 614-293-6694 or toll free at 1-888-329-1654. The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James (www.jamesline.com) is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.

# # #